The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
NCT06109558
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
RET Gene Mutation
MET Amplification
EGF-R Positive Non-Small Cell Lung Cancer
Interventions
DRUG:
LMV-12(HE003)
Sponsor
Hunan Province Tumor Hospital